Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02666612

Acronym

Liquid Biopsy

Enrollment

2240

Registered

2016-01-28

Start date

2008-08-31

Completion date

2023-08-31

Last updated

2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Cancer

Keywords

Patients

Brief summary

Monitoring of circulating endothelial cells (CEC and mature cells called progenitors called CEP) or circulating tumor cells (CTC) in adult patients with metastatic cancer, possibly treated with targeted therapy.

Interventions

PROCEDUREBlood samples

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with metastatic solid tumor * Age\> 18 years * Signed consent

Exclusion criteria

* Patients with diseases associated with vascular lesions known. * Patients protected by law, in accordance with Articles L1121-5 to L1121-8 of the Code of Public Health. * Mental pathology that can interfere with the proper conduct of the study. * Refusal of consent.

Design outcomes

Primary

Measure	Time frame	Description
Measurement and characterization of CEC and CEP and circulaing DNA rate using flow cytometry	up to 2 years	Measurement and characterization of initial CEC and CEP circulaing DNA and their evolution under treatment

Countries

France

Contacts

Primary ContactJean Charles Soria, MD-PhD

soria@gustaveroussy.fr0142114291

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026